Kubicka-Trzaska Agnieszka
Z Katedry Okulistyki Kliniki Okulistyki i Onkologii Okulistycznej, Uniwersytetu Jagiellońskiego Collegium Medicum w Krakowie.
Klin Oczna. 2010;112(10-12):333-6.
Anti-vascular endothelial growth factor (anti-VEGF) therapies that inhibit choroidal angiogenesis and reduce vascular permeability have revolutionized clinical practices for neovascular eye diseases. Ranibizumab (Lucentis) is a Fab-antibody with high affinity for VEGF, and has a potential to bind to all VEGF isoforms. Diseases of retinal and choroidal vasculature are the most prevalent causes of vision loss in developed countries. Among them diabetic macular edema (DME) is the most common sight threatening complication of diabetes. VEGF plays a critical role in the pathogenesis of DME. Due to modest outcomes with macular photocoagulation, other treatment modalities for DME have been evaluated. The results of the pilot studies and preliminary results of multicenter randomized, controlled studies showed that intraocular injections of ranibizumab decrease the mean retinal thickness and improve the BCVA (best corrected visual acuity) in patients with DME.
抑制脉络膜血管生成并降低血管通透性的抗血管内皮生长因子（抗VEGF）疗法彻底改变了新生血管性眼病的临床治疗方法。雷珠单抗（Lucentis）是一种对VEGF具有高亲和力的Fab抗体，有可能与所有VEGF异构体结合。视网膜和脉络膜血管疾病是发达国家视力丧失的最常见原因。其中糖尿病性黄斑水肿（DME）是糖尿病最常见的威胁视力的并发症。VEGF在DME的发病机制中起关键作用。由于黄斑光凝的效果一般，人们对DME的其他治疗方式进行了评估。试点研究结果和多中心随机对照研究的初步结果表明，眼内注射雷珠单抗可降低DME患者的平均视网膜厚度并改善最佳矫正视力（BCVA）。
